Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

Detalles Bibliográficos
Autores principales: Lammers, Austin, Wang, Ruibin, Cetnar, Jeremy, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802585/
https://www.ncbi.nlm.nih.gov/pubmed/29187747
http://dx.doi.org/10.1038/s41408-017-0008-9
_version_ 1783298548809334784
author Lammers, Austin
Wang, Ruibin
Cetnar, Jeremy
Prasad, Vinay
author_facet Lammers, Austin
Wang, Ruibin
Cetnar, Jeremy
Prasad, Vinay
author_sort Lammers, Austin
collection PubMed
description
format Online
Article
Text
id pubmed-5802585
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58025852018-02-08 Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals Lammers, Austin Wang, Ruibin Cetnar, Jeremy Prasad, Vinay Blood Cancer J Correspondence Nature Publishing Group UK 2017-11-30 /pmc/articles/PMC5802585/ /pubmed/29187747 http://dx.doi.org/10.1038/s41408-017-0008-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Correspondence
Lammers, Austin
Wang, Ruibin
Cetnar, Jeremy
Prasad, Vinay
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title_full Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title_fullStr Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title_full_unstemmed Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title_short Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
title_sort time from us food and drug administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802585/
https://www.ncbi.nlm.nih.gov/pubmed/29187747
http://dx.doi.org/10.1038/s41408-017-0008-9
work_keys_str_mv AT lammersaustin timefromusfoodanddrugadministrationapprovaltopublicationofdataforcancerdrugsacomparisonoffirstandsubsequentapprovals
AT wangruibin timefromusfoodanddrugadministrationapprovaltopublicationofdataforcancerdrugsacomparisonoffirstandsubsequentapprovals
AT cetnarjeremy timefromusfoodanddrugadministrationapprovaltopublicationofdataforcancerdrugsacomparisonoffirstandsubsequentapprovals
AT prasadvinay timefromusfoodanddrugadministrationapprovaltopublicationofdataforcancerdrugsacomparisonoffirstandsubsequentapprovals

Ejemplares similares